US 12,104,178 B2
DHFR tunable protein regulation
Vipin Suri, Belmont, MA (US); Dan Jun Li, Cambridge, MA (US); Dexue Sun, Cambridge, MA (US); Byron Delabarre, Arlington, MA (US); Vijaya Balakrishnan, Groton, MA (US); Brian Dolinski, Cambridge, MA (US); Mara Christine Inniss, Beverly, MA (US); and Grace Y. Olinger, Cambridge, MA (US)
Assigned to OBSIDIAN THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Obsidian Therapeutics, Inc., Cambridge, MA (US)
Filed on Dec. 28, 2021, as Appl. No. 17/646,212.
Application 17/646,212 is a continuation of application No. 16/558,224, filed on Sep. 2, 2019.
Application 16/558,224 is a continuation of application No. PCT/US2018/020718, filed on Mar. 2, 2018.
Application 16/558,224 is a continuation of application No. PCT/US2018/020741, filed on Mar. 2, 2018.
Application 16/558,224 is a continuation of application No. PCT/US2018/020755, filed on Mar. 2, 2018.
Application 16/558,224 is a continuation of application No. PCT/US2018/020768, filed on Mar. 2, 2018.
Application 16/558,224 is a continuation of application No. PCT/US2018/020704, filed on Mar. 2, 2018.
Claims priority of provisional application 62/542,400, filed on Aug. 8, 2017.
Claims priority of provisional application 62/484,047, filed on Apr. 11, 2017.
Claims priority of provisional application 62/466,603, filed on Mar. 3, 2017.
Claims priority of provisional application 62/484,052, filed on Apr. 11, 2017.
Claims priority of provisional application 62/466,601, filed on Mar. 3, 2017.
Claims priority of provisional application 62/484,062, filed on Apr. 11, 2017.
Claims priority of provisional application 62/555,316, filed on Sep. 7, 2017.
Claims priority of provisional application 62/484,060, filed on Apr. 11, 2017.
Claims priority of provisional application 62/555,328, filed on Sep. 7, 2017.
Claims priority of provisional application 62/484,063, filed on Apr. 11, 2017.
Claims priority of provisional application 62/542,402, filed on Aug. 8, 2017.
Prior Publication US 2022/0213449 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C12N 9/06 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01)
CPC C12N 9/003 (2013.01) [A61K 35/17 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/70503 (2013.01); C07K 14/7155 (2013.01); C12N 15/85 (2013.01); C12Y 105/01003 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 7 Claims
 
1. An isolated engineered T-cell comprising a nucleotide sequence that encodes a fusion polypeptide comprising membrane-bound IL15 and a destabilizing domain (DD) having the amino acid sequence of SEQ ID NO.197.